Effect of supplementation in treatment of patients with gestational diabetes

Clinical trial of the effect of selenium supplementation compared with the placebo on gene expression involved in inflammation signaling pathway in patients with gestational diabetes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201612045623N95

Enrollment

Registered

2016-12-04

Start date

2016-11-15

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational diabetes. Diabetes mellitus in pregnancy, unspecified

Interventions

Intervention 1: Intervention group: 200 µg selenium (Nature Made, California, USA), once a day, for 6 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran), once a day, fo

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with gestational diabetes aged 18 to 40 years

Exclusion criteria

Exclusion criteria: Taking selenium supplements before the intervention Needing insulin therapy Placenta abruption Pre-eclampsia Eclampsia Hypo and hyperthyroidism Smokers

Design outcomes

Primary

Measure	Time frame
TNF-a. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR-RT.	—

Secondary

Measure	Time frame
IL-1. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR-RT.;IL-8. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR-RT.;TGF-B. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR-RT.;VEGF. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR-RT.	—

Measure

Time frame

IL-1. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR-RT.;IL-8. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR-RT.;TGF-B. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR-RT.;VEGF. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR-RT.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 10, 2026